Search - tctmd.com

Displaying 841 - 860 of 900

Sort: Relevancy | Date

Presentation

RAPID GENE: Point-of-Care Genetic Testing for Personalization of Antiplatelet Treatment

Presenter: J.D. Roberts

March 29, 2012

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

Presentation ACC 2012

RESET Study: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose versus Prasugrel

Presenter: Gennaro Sardella

March 24, 2012

Presentation ACC 2012

First Pharmacogenomic Analysis Using Whole Exome Sequencing to Identify Novel Genetic Determinants of Clopidogrel

Presenter: Matthew Price

March 24, 2012

Presentation ACC 2012

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Presenter: Hyo-Soo Kim

March 24, 2012

Presentation PCI Outcomes 2012

PCI in NSTEMI and STEMI: Essentials of Pharmacology

Presenter: C. Michael Gibson

March 23, 2012

Presentation PCI Outcomes 2012

Optimizing Pharmacology Before, During and After PCI

Presenter: E. Magnus Ohman

March 23, 2012

Presentation

El Tabaquismo se asocia a un Efecto Dosis-Respuesta en Pacientes tratados con Clopidogrel con Diabetes Mellitus y EAC

Presenter: M. Ueno

March 19, 2012

Presentation

Cigarette Smoking Associated with a Dose-Response Effect in Clopidogrel-Treated Patients with Diabetes Mellitus and CAD

Presenter: M. Ueno

March 19, 2012

Presentation

Reduced Immediate Ischemic Events with Cangrelor in PCI: Pooled Analysis of the CHAMPION Trials Using the Universal Definition of MI

Presenter: 35236|Harvey White

March 16, 2012

Presentation

Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing CABG

Presenter: E. Mahla

March 13, 2012

Presentation

Estrategia basada en Medir la Función Plaquetaria para Reducir las Hemorragias en el Tiempo de Espera en Pacientes Tratados con Clopidogrel que se someten a un CABG

Presenter: E. Mahla

March 13, 2012

Presentation

Apixaban vs. Aspirin in Patients with A-fib and Previous Stroke or TIA

Presenter: Hans-Christoph Diener

March 08, 2012

Presentation

Meta-Analysis of RCTs on Effect of Cilostazol on Restenosis and Outcomes After PCI

Presenter: S. Friedland

March 06, 2012

Presentation

Meta-Análisis of Ensayos Controlados Aleatorizaos sobre el Efecto del Cilostazol en la Re-estenosis y Resultados tras PCI

Presenter: S. Friedland

March 06, 2012

Presentation

Impact of Statin Therapy on Late TLR After Sirolimus-Eluting Stent (SES) Implantation

Presenter: 202206|M Natsuaki

March 04, 2012

Presentation

Impacto de la Anemia en la Respuesta Plaquetaria al Clopidogrel en Pacientes sometidos a PCI

Presenter: C. Toma

February 14, 2012

Presentation

Impact of Anemia on Platelet Response to Clopidogrel in Patients Undergoing PCI

Presenter: Catalin Toma

February 14, 2012

Presentation

¿Existe una Interacción Clínica Significativa Entre los Bloqueadores de los Antagonistas de los Canales del Calcio y Clopidogrel?

Presenter: Christopher W. Good

February 12, 2012

Presentation

Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel?

Presenter: Christopher W. Good

February 12, 2012

Advertisement

RAPID GENE: Point-of-Care Genetic Testing for Personalization of Antiplatelet Treatment

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

RESET Study: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose versus Prasugrel

First Pharmacogenomic Analysis Using Whole Exome Sequencing to Identify Novel Genetic Determinants of Clopidogrel

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

PCI in NSTEMI and STEMI: Essentials of Pharmacology

Optimizing Pharmacology Before, During and After PCI

El Tabaquismo se asocia a un Efecto Dosis-Respuesta en Pacientes tratados con Clopidogrel con Diabetes Mellitus y EAC

Cigarette Smoking Associated with a Dose-Response Effect in Clopidogrel-Treated Patients with Diabetes Mellitus and CAD

Reduced Immediate Ischemic Events with Cangrelor in PCI: Pooled Analysis of the CHAMPION Trials Using the Universal Definition of MI

Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing CABG

Estrategia basada en Medir la Función Plaquetaria para Reducir las Hemorragias en el Tiempo de Espera en Pacientes Tratados con Clopidogrel que se someten a un CABG

Apixaban vs. Aspirin in Patients with A-fib and Previous Stroke or TIA

Meta-Analysis of RCTs on Effect of Cilostazol on Restenosis and Outcomes After PCI

Meta-Análisis of Ensayos Controlados Aleatorizaos sobre el Efecto del Cilostazol en la Re-estenosis y Resultados tras PCI

Impact of Statin Therapy on Late TLR After Sirolimus-Eluting Stent (SES) Implantation

Impacto de la Anemia en la Respuesta Plaquetaria al Clopidogrel en Pacientes sometidos a PCI

Impact of Anemia on Platelet Response to Clopidogrel in Patients Undergoing PCI

¿Existe una Interacción Clínica Significativa Entre los Bloqueadores de los Antagonistas de los Canales del Calcio y Clopidogrel?

Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content